Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Study of Standard Systemic Therapy in Treating Prostate Cancer

Clinical Trial Title: 
Phase III randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer.
Clinical Trial Protocol ID: 
18111508
Clinical Trial Investigator Name: 
Srinivas Vourganti, MD
Clinical Trial Protocol Description: 

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
  • Have an intact prostate.
  • Have received no more than 28 weeks of standard systemic therapy (SST).

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-5526
Contact Name: 
Pamela Sroka, RN